Redburn Atlantic initiated coverage of Thermo Fisher with a rating of Buy
Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 10/14/2024 | Buy | Redburn Atlantic | |
| 10/1/2024 | $680.00 | Overweight | Stephens |
| 8/28/2024 | $670.00 | Overweight | Wells Fargo |
| 6/3/2024 | $650.00 | Buy | Jefferies |
| 3/18/2024 | $620.00 | Neutral | Citigroup |
| 1/24/2024 | $475.00 → $555.00 | Overweight → Equal Weight | Barclays |
| 1/8/2024 | Outperform → Mkt Perform | Bernstein | |
| 12/18/2023 | $610.00 | Buy | HSBC Securities |
Thermo Fisher Scientific Inc. (NYSE:TMO), the world leader in serving science, today announced that its Board of Directors has authorized the repurchase of $4 billion of shares of its common stock in the open market or in negotiated transactions. The authorization has no expiration date. This replaces the company's existing repurchase authorization, of which $1 billion was remaining. About Thermo Fisher Scientific Thermo Fisher Scientific Inc. is the world leader in serving science, with annual revenue of approximately $40 billion. Our Mission is to enable our customers to make the world healthier, cleaner and safer. Whether our customers are accelerating life sciences research, solving
BERKELEY, Calif. and MAINZ, Germany, Nov. 12, 2024 (GLOBE NEWSWIRE) -- Mainz Biomed N.V. (NASDAQ:MYNZ) ("Mainz Biomed" or the "Company"), a molecular genetics diagnostic company specializing in the early detection of cancer, today announced a collaborative agreement with Thermo Fisher Scientific Inc. (NYSE:TMO), through its subsidiary Life Technologies Corporation ("Thermo Fisher"), a world leader in supplying life sciences solutions and services. The collaboration agreement will enable Mainz Biomed and Thermo Fisher to jointly develop and potentially commercialize Mainz Biomed's Next Generation colorectal cancer screening product. The collaboration will harness Thermo Fisher's
Thermo Fisher Scientific Inc. (NYSE:TMO), the world leader in serving science, announced that Marc N. Casper, chairman, president and chief executive officer, will present at the Wolfe Healthcare Conference on Tuesday, November 19, 2024 at 8:00 a.m. (EDT). You can access the live webcast of the presentation via the Investors section of our website, www.thermofisher.com. About Thermo Fisher Scientific Thermo Fisher Scientific Inc. is the world leader in serving science, with annual revenue over $40 billion. Our Mission is to enable our customers to make the world healthier, cleaner and safer. Whether our customers are accelerating life sciences research, solving complex analytical challen
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page. Baird increased Apple Inc. (NASDAQ:AAPL) price target from $200 to $240. Baird analyst William Power maintained an Outperform rating. Apple shares fell 0.1% to trade at $218.51 on Thursday. See how other analysts view this stock. Truist Securities raised the price target for ServiceNow, Inc. (NYSE:NOW) from $750 to $780. Truist Securities analyst Joel Fishbein maintained a Hold rating. ServiceNow shares gained 11.9% to trade at $817.75 on Thursday. See how other analysts view this stock. JP Morg
Stifel analyst Daniel Arias maintains Thermo Fisher Scientific (NYSE:TMO) with a Buy and raises the price target from $600 to $615.
4 - THERMO FISHER SCIENTIFIC INC. (0000097745) (Issuer)
4 - THERMO FISHER SCIENTIFIC INC. (0000097745) (Issuer)
4 - THERMO FISHER SCIENTIFIC INC. (0000097745) (Issuer)
SC 13G/A - THERMO FISHER SCIENTIFIC INC. (0000097745) (Subject)
SC 13G/A - THERMO FISHER SCIENTIFIC INC. (0000097745) (Subject)
Thermo Fisher Scientific Inc. (NYSE:TMO), the world leader in serving science, today announced that its Board of Directors authorized a quarterly cash dividend of $0.39 per common share, payable on January 15, 2025, to shareholders of record as of December 13, 2024. About Thermo Fisher Scientific Thermo Fisher Scientific Inc. is the world leader in serving science, with annual revenue over $40 billion. Our Mission is to enable our customers to make the world healthier, cleaner and safer. Whether our customers are accelerating life sciences research, solving complex analytical challenges, increasing productivity in their laboratories, improving patient health through diagnostics or the dev
Thermo Fisher Scientific Inc. (NYSE:TMO), the world leader in serving science, today reported its financial results for the third quarter ended September 28, 2024. Third Quarter 2024 Highlights Third quarter revenue was $10.60 billion. Third quarter GAAP diluted earnings per share (EPS) was $4.25. Third quarter adjusted EPS was $5.28. Advanced our proven growth strategy, launching a range of high-impact, innovative new products during the quarter. To enable the development of advanced materials, we launched the groundbreaking Thermo Scientific Iliad scanning transmission electron microscope, which integrates a number of our advanced technologies into a user-friendly workflow to en
Thermo Fisher Scientific Inc. (NYSE:TMO), the world leader in serving science, announced that it will release its financial results for the third quarter 2024 before the market opens on Wednesday, October 23, 2024, and will hold a conference call on the same day at 8:30 a.m. EDT. During the call, the company will discuss its financial performance, as well as future expectations. To listen, call (833) 470-1428 within the U.S. or (404) 975-4839 outside the U.S. The access code is 296868. You may also listen to the call live on the "Investors" section of our website, www.thermofisher.com. The earnings press release and related information can also be found in that section of our website under
Redburn Atlantic initiated coverage of Thermo Fisher with a rating of Buy
Stephens initiated coverage of Thermo Fisher with a rating of Overweight and set a new price target of $680.00
Wells Fargo initiated coverage of Thermo Fisher with a rating of Overweight and set a new price target of $670.00
10-Q - THERMO FISHER SCIENTIFIC INC. (0000097745) (Filer)
144 - THERMO FISHER SCIENTIFIC INC. (0000097745) (Subject)
8-K - THERMO FISHER SCIENTIFIC INC. (0000097745) (Filer)
Files Preliminary Proxy Statement to Solicit Shareholders to Oppose the Merger Intends to Vote AGAINST the Conflict-Plagued and Excessively Dilutive Transaction, Which Stands to Unduly Benefit Certain Investors and Standard BioTools at the Expense of SomaLogic's Shareholders Notes the Current Premium for SomaLogic Shareholders, Based on the Deal's Exchange Ratio and Standard BioTools' Trading Price, is Only ~4.3% Underscores That SomaLogic Has Superior Alternatives to a Flawed Combination, Including a Standalone Path Leveraging its Considerable Cash Position and Strong Balance Sheet Madryn Asset Management, LP (collectively with its affiliates, "Madryn"), a holder of approximately 4
Traci Kyes and Makis Sigalas bring extensive industry experience to roles focused on expanding ViroCell's business in the US and Europe Team ViroCell will be attending the Cell & Gene Therapy Meeting on the Mesa, 10-12 October 2023 ViroCell Biologics ("ViroCell" or the "Company"), a specialist contract development and manufacturing organisation ("CDMO") in cell and gene therapy clinical trials, announces the appointment of Traci Kyes as Vice President (VP) of Business Development (US) and Makis Sigalas as Senior Business Development Director (Europe). Focused on driving growth in the US and Europe, respectively, Traci and Makis bring a wealth of business development expertise to ViroCel
FORT LAUDERDALE, Fla. and Sacramento, Calif., March 16, 2023 /PRNewswire/ -- Gemini BioProducts Holding, Inc. ("GeminiBio" or the "Company"), a portfolio company of BelHealth Investment Partners, LLC ("BelHealth"), a Florida-based healthcare private equity firm, announced the appointment of Cory Stevenson as Executive Chairman of the Board of Directors. GeminiBio Appoints Industry Veteran Cory Stevenson as Executive ChairmanMr. Stevenson joined the Board of GeminiBio in 2022 and has been working closely with the GeminiBio management team as they prepare to complete a three-pha
4 - THERMO FISHER SCIENTIFIC INC. (0000097745) (Issuer)